Skip to main content

Month: May 2020

Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress

Results from positive Phase 3 PEGASUS study in PNH selected for oral presentation at the 2020 European Hematology Association CongressPEGASUS showed superiority of pegcetacoplan to eculizumab in improving hemoglobin levels as well as clinically meaningful improvements in key additional hematologic and clinical outcomes at 16 weeksWALTHAM, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that results from the Phase 3 PEGASUS study were selected for oral presentation at the 25th Annual Congress of the European Hematology Association. The abstract has been published on the EHA website, and the oral presentation, featuring additional analysis of the 16-week PEGASUS data, will be available online during the virtual...

Continue reading

SeaBird Exploration Plc: Annual General Meeting 2020 completed

14 May 2020, Limassol, CyprusThe Annual General Meeting (the “AGM”) of SeaBird Exploration Plc (“SeaBird”) is completed. All proposals on the agenda, as proposed by the board of directors and set out in the notice of the meeting announced on 22 April 2020, were adopted with requisite majority.After the AGM, SeaBird’s board of directors consists of Mr. Ståle Rodahl (Chairman), Mr. Nicholas Knag Nunn, Mr. Øivind Dahl-Stamnes and Mr. Rolf Inge Jacobsen.SeaBird is a global provider of marine acquisition for 2D/3D and 4D seismic data, and associated products and services to the oil and gas industry. SeaBird specializes in high quality operations within the high end of the source vessel and 2D market, as well as in the shallow/deep water 2D/3D and 4D market. Main focus for the company is proprietary seismic surveys...

Continue reading

Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19

May 14, 2020News releaseDanish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19The Innovation Fund Denmark has awarded DKK 3 million to test if the drug Iloprost can improve survival rates in SARS-Co-V2 infected patients in need of respiratory treatment. The study will be conducted in a partnership between leading hospitals in the Capital Region of Denmark and BioPorto A/S, a Danish diagnostics company.More than half of all COVID-19 patients on life support and in intensive care will not survive the disease. The primary cause of mortality in this population is Adult Respiratory Distress Syndrome (ARDS). Research by Professor Pär I Johansson from the Clinical Immunology Department at Rigshospitalet in Copenhagen, Denmark, points to damage to the capillaries, leading to reduced blood flow and oxygen...

Continue reading

Forskningsgruppe skal teste behandling til de mest kritisk syge patienter ramt af COVID-19

May 14, 2020News releaseForskningsgruppe skal teste behandling til de mest kritisk syge patienter ramt af COVID-19Innovationsfonden har doneret tre millioner kroner til at teste, hvorvidt lægemidlet Iloprost kan forbedre overlevelsen hos coronainficerede patienter med behov for respiratorbehandling. Testen gennemføres i et samarbejde mellem en række førende hospitaler i Region Hovedstaden samt BioPorto A/S.Flere end halvdelen af alle intensivpatienter med COVID-19 i respiratorbehandling overlever ikke. Den hyppigste dødsårsag er akut lungesvigt, og forskning ledet af Professor Pär I. Johansson fra Klinisk immunologisk Afdeling på Rigshospitalet tyder på, at dette skyldes skade på kroppens mindste kar (kapillærer), som leder til dårlig blodgennemstrømning og iltmangel i kroppens vigtigste organer med høj dødelighed til følge.Forskningsgruppen...

Continue reading

ISG to Release Study of Contact Center Services, with Focus on COVID-19 Pandemic

STAMFORD, Conn., May 14, 2020 (GLOBE NEWSWIRE) — Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, has launched a research study examining the contact center outsourcing market, including the ability of providers to deliver services during the COVID-19 pandemic.The study results will be published in a comprehensive ISG Provider Lens™ report, called Contact Center – Customer Experience, scheduled to be released in September. The report will cover outsourcing providers offering contact center and related services, and examine such core success metrics as a provider’s ability to offer services in multiple languages, to implement design thinking elements, to incorporate artificial intelligence and to include cloud-based services.As companies deal with the impacts of the COVID-19 pandemic,...

Continue reading

Truxton Corporation Named 17th Top Bank in U.S. by American Banker

Honored for 3-year return on average equityRecognized as a top bank for the eighth year in a rowOnly ranked bank in NashvilleNASHVILLE, Tenn., May 14, 2020 (GLOBE NEWSWIRE) — Truxton Corporation (OTCPK: TRUX), a financial holding company and the parent of Truxton Trust Company, announced that it has been recognized by American Banker as one of the top 200 best performing banks in the nation. Truxton Corporation has earned this recognition for eight consecutive years and is the only Nashville bank to make the list this year.American Banker’s annual ranking of publicly traded banks with less than $2 billion of assets is determined by return on average equity across three years. Truxton Corporation ranked 17 out of 511 institutions that qualified for the ranking, with a 3-year return on average equity of 14.64 percent. Andrew May,...

Continue reading

Marathon Patent Group Announces 2020 Fiscal First Quarter Financial Results

LAS VEGAS, May 14, 2020 (GLOBE NEWSWIRE) — Marathon Patent Group, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), today announced its operating results for the three months ended March 31, 2020. The Company anticipates filing its Form 10-Q with the Securities and Exchange Commission later today.Summary of Operating Results for the Quarter Ended March 31, 2020Reported revenues of $592,487 during the three months ended March 31, 2020 as compared to $230,694 during the three months ended March 31, 2019, an increase of 157% over the same period in 2019.Operating loss was approximately $1.1 million (inclusive of non-cash expenses) for the quarter ended March 31, 2020 compared to an operating loss of approximately $1 million (inclusive of non-cash expenses) for the quarter ended March 31, 2019.Per share net loss improved...

Continue reading

First Citizens Bank Helps Nearly 23,000 Business Clients Access SBA Paycheck Protection Program Funding

RALEIGH, N.C., May 14, 2020 (GLOBE NEWSWIRE) — First Citizens Bank today announced it has helped nearly 23,000 businesses across the company’s franchise secure loans totaling $3.2 billion through the SBA’s Paycheck Protection Program.“Taking care of our customers is our promise – it’s who we are, especially during times like these,” said Chairman and CEO Frank Holding. “I’d like to thank our clients for their patience and trust in us as we’ve navigated this process and the unusual operating environment. I’d also like to thank our associates for diligently working day and night to help businesses access this PPP funding. It’s been an incredible display of teamwork and dedication, and we’re grateful for the opportunity to support small businesses and their vital role in the communities we serve.”The Paycheck Protection Program, part...

Continue reading

Unity Bank is Top Ranked New Jersey Community Bank on American Banker Magazine’s Top 200 List

CLINTON, N.J., May 14, 2020 (GLOBE NEWSWIRE) — Unity Bancorp, Inc. (NASDAQ: UNTY), the parent company of Unity Bank, was the top ranked New Jersey community bank on the recently published American Banker magazine list of the Top 200 Publicly Traded Community Banks with less than $2 billion in assets. Unity was ranked 15th nationally on the respected industry list, which reviewed 511 institutions throughout the U.S.“We are honored to be the top ranked community bank in New Jersey on the American Banker list as it illustrates Unity’s continued financial strength and performance,” said Unity Bank President & CEO James A. Hughes. “The bank’s fiscal health could not be more important given the business challenges presented by the coronavirus crisis. Unity is better positioned to invest in the community because of our financial stability....

Continue reading

Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation –– Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET –CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that mitapivat and ivosidenib clinical data will be presented at the European Hematology Association (EHA) Annual Congress being held virtually June 11-14, 2020.The accepted abstracts are listed below and are available online on the EHA meeting library website: https://eha25-eha.web.indrina.com/abstracts. All presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform as of Friday, June 12 at 08:30 a.m. CEST / 2:30 a.m. ET and will be accessible...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.